Drug treatments in development for Alzheimer's disease

Journal of Pharmacy Practice and Research

Volumn 42, Issue 1, 2012, Pages 58-65

  Woodward, Michael C ^a  

^a HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AF 267B; ALPHA SECRETASE INHIBITOR; AMPA RECEPTOR AGONIST; AMYLOID; ANTIOXIDANT; ASP 1702; BETA SECRETASE INHIBITOR; CEREBROLYSIN; COLOSTRININ; CTS 21166; CURCUMIN; DIMEBON; ETANERCEPT; GAMMA SECRETASE INHIBITOR; GANTENERUMAB; GRL 8234; HISTAMINE H3 RECEPTOR ANTAGONIST; HOMOTAURINE; KMI 429; LY 2811376; METHYLENE BLUE; MK 0752; MUSCARINIC AGENT; NERVE GROWTH FACTOR; NEW DRUG; NICOTINIC AGENT; POLYCLONAL ANTIBODY; SELENIUM; SEMAGACESTAT; SEROTONIN 6 ANTAGONIST; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; DEMENTIA; HUMAN; INFLAMMATION; NERVOUS SYSTEM DEVELOPMENT; OXIDATIVE STRESS; REVIEW;

EID: 84859652393     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2012.tb00133.x     Document Type: Review

References (64)

1. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 241-5.
2. Woodward M. Behavioural and psychological symptoms of dementia. In: Caplan G, editor. Dementia. Sydney: IP Communications. In press.
3. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65: 896-905.
4. Woodward M. Anti-inflammatory drugs. In: Ritchie CW, Ames D, Masters CL, Cummings J, editors. Therapeutic strategies in dementia. Oxford: Atlas Medical Publishing; 2007. pp. 111-19.
5. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in PDAPP mouse. Nature 1999; 400: 173-7.
6. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-5.
7. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic AE42 (AN1792) in patients with AD. Neurology 2005; 64: 94-101.
8. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningo-encephalitis in a subset of patients with AD after AS42 immunization. Neurology 2003; 61: 46-54.
9. Hock C, Konietzko U, Steffer JR, Tracy J, Signorell A, Müller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-54.
10. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of AL42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-23.
11. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-42.
12. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73: 2061-70.
13. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C PiB-PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-72.
14. Blennow K, Zetterberg H, Wei J, Liu E, Black R, Grundman M. Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease [abstract]. Proceedings of the Alzheimer's Association International Conference on Alzheimer's Disease; 2010 July 10-15; Honolulu, Hawaii. Honolulu: The Association; 2012.
15. Siemers ER, Dean RA, Lachno DR, Zajac JJ, Sethuraman G, DeMattos RB, et al. Measurement of cerebrospinal fluid total tau and phospho-tau in phase 2 trials of therapies targeting At. Alzheimers Dement 2009; 5: 258.
16. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7: 367-85.
17. Fillit H, Hess G, Hill J, Bonnet P, Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009; 73: 180-5.
18. Panza F, Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, et al. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 2009; 26: 537-55.
19. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65: 1031-8.
20. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009; 66: 48-54.
21. Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, et al. Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 2011; 20: 325-41.
22. Rosen LB, Stone JA, Plump A, Yaun J, Harrison T, Flynn M, et al. The gammasecretase inhibitor MK-0752 acutely and significantly reduces CSF Ai concentrations in humans [abstract]. Alzheimers Dement 2006; 2 (suppl): S79.
23. Kuker TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, et al. Substrate-targeting gamma-secretase modulators. Nature 2008; 453: 925-9.
24. Vassar R, Kandalepas PC. The K-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimers Res Ther 2011; 3: 20.
25. Aisan PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, et al. A phase I study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006; 67: 1757-63.
26. Garcia-Alloza M, Borrelli LA, Rozkaine A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores neuritis in an Alzheimer mouse model. J Neurochem 2007; 102: 1095-104.
27. Cheney RA, Atwood CS, Xilinas E, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits betaamyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-76.
28. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting ASSas a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebocontrolled trial. Lancet Neurol 2008; 7: 779-86.
29. Leszek J, Inglot AD, Janusz M, Byczkiewicz F, Kiejna A, Georgiades J, et al. Colostrinin proline-rich polypeptide complex from ovine colostrum-a long-term study of its efficacy in Alzheimer's disease. Med Sci Monit 2002; 8: 193-6.
30. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. AW42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signalling through the APP intracellular domain. J Biol Chem 2003; 278: 30748-54.
31. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower AN42 in vivo. J Clin Invest 2003; 112: 440-9.
32. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, et al. Safety, tolerability, pharmacokinetics, and A beta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimers Dis Assoc Disord 2007; 21: 292-9.
33. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008; 7: 483-93.
34. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer Disease. JAMA 2009; 302: 2557-64.
35. Frenkel D, Puckett L, Petrovic S, Xia W, Chen G, Vega J, et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann Neurol 2008; 63: 591-601.
36. Gong CX, Grundke-Iqbal I, Iqbal K. Targeting tau protein in Alzheimer's disease. Drugs Aging 2010; 27: 351-65.
37. Wischik CM, Bentham P, Wischik DJ, Seng KM. Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks [abstract]. Alzheimers Dement 2008; 4 (suppl): T167.
38. van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Götz J, et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci USA 2010; 107: 13888-93.
39. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, et al. A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-5.
40. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, et al. A 24-week, double-blind, placebo-controlled study of three doses of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006; 13: 43-54.
41. Doody RS. We should not distinguish between symptomatic and diseasemodifying treatments in Alzheimer's disease drug development. Alzheimers Dement 2008a; 4 (suppl 1): S21-S25.
42. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007; 321: 1032-45.
43. Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008; 5: 458-69.
44. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 2002; 16: 811-24.
45. Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement 2008; 4: 65-79.
46. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008; 5: 2.
47. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008; 372: 207-15.
48. Jones RW. Dimebon disappointment. Alzheimers Res Ther 2010; 2: 25.
49. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1216-22.
50. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-88.
51. Frank B, Gupta S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 2005; 17: 269-86.
52. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer's disease: preliminary results. Arch Neurol 2005; 62: 753-7.
53. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease. Neurology 2010; 74: 956-64.
54. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomised, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77: 556-63.
55. Craft S. Insulin resistance syndrome and Alzheimer's disease: age and obesityrelated effects on memory, amyloid and inflammation. Neurobiol Aging 2005; 26 (suppl 1): S65-S69.
56. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer's disease and amnestic mild cognitive impairment after treatment with rosiglitazone; a preliminary study. Am J Geriatr Psychiatry 2005; 13: 950-8.
57. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, et al. Rosiglitazone does not improve cognition or global function when used as an adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 2011; 8: 592-606.
58. Casadeus G, Zhu X, Atwood CS, Webber KM, Perry G, Bowen RL, et al. Beyond oestrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease. Curr Drug Targets CNS Neurol Discord 2004; 3: 281-5.
59. Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006; 27: 451-8.
60. Sheshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
61. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 5644-51.
62. Shah RC. Medical foods for Alzheimer's disease. Drugs Aging 2011; 28: 421-8.
63. Stough C, Downey LA, Lloyd J, Silber B, Redman S, Hutchison C, et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Psychother Res 2008; 22: 1629-34.
64. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-46.